samedan logo
 
 
 
spacer
home > ebr > autumn 2018 > targeted technology
PUBLICATIONS
European Biopharmaceutical Review

Targeted Technology

By recognising the market value of a new class of bioelectronic medicine, which is based on biosensors, electronics, nanotechnology, and biotechnology research foundations, this article puts perspective forward on bringing the technology from lab to market. Here, a comprehensive review is provided on the progress and development of bioelectronic medicine in academia, clinical hospitals, and industrial settings.

‘Bioelectronics’ was first defined in 1991 as “the use of biological materials and biological architectures for information processing and new devices” (1). Furthermore, bioelectronics can be broadly elaborated as a fusion of electronics with biological systems where an electronic device facilitates in the transduction of signal from the biological systems to electrical device in the human body at a bioelectronic interface. R&D in bioelectronics has resulted in vital medical electronics devices, such as brain stimulators, glucose sensors, and pacemakers (2-4). This article will elaborate upon the current development of bioelectronics in academia and industry and, in addition, offer a future perspective with respect to the use of bioelectronic devices for precision medicine.

Bioelectronics in Precision Medicine

Interests in both clinical and fundamental research, with respect to personalised and precision medicine, are increasing. Personalised and precision medicine promises to revolutionise existing medical treatment. According to the Precision Medicine Initiative, precision medicine is defined as “an emerging approach for disease treatment and prevention that takes into account individual variability in genes, environment, and lifestyle for each person.” Research has established a bioelectronic ecosystem consisting of portable biosensors and biomedical nano-robots that combine health monitoring with medical therapy (5). Such bioelectronic devices offer distinct advantages towards precision medicine.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Dr Deepak B Thimiri Govinda Raj holds a BTech in biotechnology from Bharathidasan University Trichy, India, and an ME in biotechnology from Birla Institute of Technology and Science, India. Deepak also has a PhD in biomedical sciences from KU Leuven, Belgium. Deepak is Co-Founder at DTCG® Consulting and Envirotransgene® Biosolutions Global. 

Prasanna Subramaniam has a BTech in biotechnology from Bharathidasan University Trichy, India, and an MTech in biopharmaceutical engineering and technology from Anna University, India. Prasanna has 12 years of experience in bioprocessing technology and biopharmaceutical operations. He is currently working as Deputy Manager at Biocon.

Dr Sri Saran Venkatachalam earned his BSc in applied sciences and MA of science in materials from Anna University, India. Sri also has a PhD in material science from the Institute of Electronics, Microelectronics, and Nanotechnology, France. He has 10 years of research and teaching experience in material science and electronics. Currently, he is an Assistant Professor at Bannari Amman Institute of Technology, India.

Dinh-Toi Chu PhD received a doctor of veterinary medicine degree at the Vietnam National University of Agriculture, Vietnam, an MA of biological science at the University of Ulsan, South Korea, and then a PhD in medicine at the Polish Academy of Sciences in Olsztyn and Medical University of Bialystok, Poland. Dinh-Toi has been a researcher and lecturer in immunology, cell biology, and animal pathology.
spacer
Dr Deepak B Thimiri Govinda Raj
spacer
spacer
spacer
Prasanna Subramaniam
spacer
spacer
spacer
Dr Sri Saran Venkatachalam
spacer
spacer
spacer
Dinh-Toi Chu PhD
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Luina Bio Announces New Bio-Manufacturing GMP And Development Facility Expansion

1st September 2020 Highlights • Small scale GMP manufacturing suites open in Q3 2020 • 500L tech transfer and process development site aim for open Q4 2020 • This precedes the next phase with Luina planning to commission a 10,000m2 late phase clinical and commercial production facility targeting late 2021 • New facilities capture more of the global value chain supporting technically advanced microbiome projects • New expanded capacity for bacterial and yeast recombinant projects including vaccine manufacturing including COVID-19 candidates
More info >>

White Papers

The BioPharmaSpec Approach”: Mass Spectrometry Based Host Cell Protein Identification and Quantitation

BioPharmaSpec

1. Introduction As part of the development of any biopharmaceutical product, the impurities present must be examined, minimized and where possible characterized (1). These impurities fall into two broad categories: product-related impurities (derived specifically from the drug product itself) and process-related impurities (derived from material associated with the production, processing or purification of the sample). Host cell proteins (HCPs) are process-related impurities that require specific analysis due to the multitude of naturally occurring proteins expressed in the production cell line.
More info >>

 
Industry Events

BIO-Europe Digital

26-29 October 2020, Digitally delivered

Global connections are more important than ever. With the same powerful one-to-one partnering and valuable content, BIO-Europe Digital continues to help you drive your life science partnering forward.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement